Kidney Cancer

The risk for disease progression or death was reduced by 27% with the addition of cabozantinib to nivolumab plus ipilimumab in patients with previously untreated renal cell carcinoma.

The final readout of the phase 2 TITAN-RCC trial highlighted an improvement in responses following an individualized regimen of nivolumab and ipilimumab boost after single-agent nivolumab in patients with advanced renal cell carcinoma.

Patients with advanced clear cell renal cell carcinoma given lenvatinib plus pembrolizumab had sustained overall survival and progression-free survival benefit vs sunitinib, according to updated results of the CLEAR trial.

Patients with localized recall cell carcinoma did not have improved disease-free survival with adjuvant nivolumab plus ipilimumab vs placebo.

Phase 3 data regarding perioperative nivolumab did not show recurrence-free survival benefit, but data from the study may help inform future research.

Data from the phase 3 IMmotion010 trial revealed no benefit of adjuvant atezolizumab vs placebo for resectable renal cell carcinoma.

Patients with clear cell renal cell carcinoma may experience successfully downstaging of venous tumor thrombus extent with neoadjuvant axitinib.

A health-related quality of life survey found similar outcomes between those treated with pembrolizumab plus axitinib vs sunitinib in advanced renal cell carcinoma.

A panel of oncologists reviews a publication by Robert J. Motzer, MD, and colleagues on data from the CLEAR trial examining lenvatinib plus either pembrolizumab or everolimus for advanced renal cell carcinoma.

The primary end point of progression-free survival was met in the phase 3 COSMIC-313 trial which investigated cabozantinib, nivolumab, and ipilimumab in previously untreated, advanced intermediate- or poor-risk renal cell carcinoma.

Experts share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma and comment on emerging data in the field.

Patients with very high-risk renal cell carcinoma experienced a notable relapse-free survival benefit vs placebo following treatment with everolimus.

Lenvatinib plus pembrolizumab decreased the risk of disease progression or death on second-line therapy by 50% compared with sunitinib in the phase 3 CLEAR trial.

Results of the phase 3 EVEREST trial show adjuvant everolimus improved recurrence-free survival for patients with very high-risk renal cell carcinoma.

Interim results from the phase 2 PADRES trial demonstrated that partial nephrectomy may be possible for a subgroup of patients with clear cell renal cell carcinoma with complex masses who received neoadjuvant axitinib.

Results from the phase 2 BIONIKK trial highlighted the feasibility and positive impact of selecting patients with metastatic clear cell renal cell carcinoma for treatment with nivolumab plus or minus ipilimumab and a VEGFR-tyrosine kinase inhibitor based on molecular phenotype.

Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

Patients with advanced renal cell carcinoma who were treated with lenvatinib plus pembrolizumab had health-related quality of life comparable with sunitinib.

In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.

Five-year follow-up findings highlighted a durable benefit among patients with advanced renal cell carcinoma following treatment with nivolumab plus ipilimumab compared with sunitinib.

Gennady Bratslavsky, MD, at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, spoke about which research in renal cell carcinoma has the greatest potential for clinical impact.

Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.

Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.

Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.

Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.

Findings from a preplanned analysis assessing 2 clinical trials of bempegaldesleukin plus nivolumab in renal cell carcinoma and bladder cancer led to a decision to end the combination’s global clinical development program and discontinue all other ongoing clinical trials.